Preparation of highly purified human cytomegalovirus envelope antigen

Flu-like symptoms and hyperechoic foetal bowel

Images

Delayed type hypersensitivity to human cytomegalovirus

A skin test for immunity to human cytomegalovirus (HCMV) is described in which skin induration is measured after intradermal injection of antigen derived from heat-inactivated Towne strain HCMV or of envelope prepared from the virus. Randomly selected healthy young adult males and females were prescreened for evidence of past infection with HCMV using serologic tests. Each individual was inoculated with heat inactivated whole virion HCMV antigen prepared from serum-free supernatants of HCMV-infected MRC-5 cells, non-infected MRC-5 cell lysates, and Candida extract. HCMV seropositive individuals developed positive skin reactions to both the Candida extract and the HCMV test antigen. No response was observed at the MRC-5 cell lysate inoculation site. The envelope antigen also elicited a response in seropositive individuals. Seronegative individuals who were negative to the HCMV intradermal antigen at the start of the study developed a positive response 1 week after subcutaneous immunization with live attenuated Towne strain HCMV. This response also correlated with the onset of in vitro proliferation responses to HCMV antigens by peripheral blood lymphocytes obtained from the immunized individuals. Furthermore, skin test and lymphocyte proliferation responses remained positive when tested up to 93 days post-immunization. In guinea pig experiments with HCMV, those animals immunized with purified HCMV or a virus envelope preparation developed strong skin reactions to intradermal injection of each of those antigens. In contrast, no reaction was observed in immune animals, either to viral capsid antigen or uninfected cell-lysate antigen, and no reactions were observed to any HCMV antigen in non-immune animals.

Genomic locus for a 140 kDa structural protein (pp150) of human cytomegalovirus in strains Towne and AD169

An HCMV specific clone was isolated from a genomic library of human cytomegalovirus (HCMV) DNA cloned into the expression vector lambda gt11. This clone (lambda 111-1) expressed an HCMV/beta-galactosidase fusion protein which was reactive with rabbit antibody prepared against purified HCMV virions and dense bodies as well as human HCMV immune serum. By probing Western blots of HCMV virion proteins or HCMV-infected cells with antibody prepared against the fusion protein, the authentic gene product of clone lambda 111-1 was identified as a high molecular weight polypeptide of 140. Probing the restriction digests of HCMV DNA with insert DNA from the immunoreactive lambda gt11 clone permitted us to localize the coding sequence for the 140 kDa polypeptide to the long unique region (map coordinates of 0.16-0.18) on HCMV Towne and AD169 genomes.

Genomic localization of the gene encoding a 32-kDa capsid protein of human cytomegalovirus

We have determined the map position of a viral gene encoding a 32-kDa late structural protein of human cytomegalovirus (HCMV) using a murine monoclonal antibody. This monoclonal antibody was reactive with two protein bands of 32 and 27 kDa in HCMV-infected cell lysates and with a single 32-kDa protein band in HCMV virions as detected by immunoblot analysis. When purified HCMV envelope preparation was used for immunoblotting, the monoclonal antibody did not display a detectable band. We used this monoclonal antibody to screen a cDNA library that was constructed from poly(A)+ RNA of late HCMV-infected cells and cloned into the expression vector lambda gt11. A cDNA clone that expressed an immunoreactive epitope of the late HCMV protein fused to beta-galactosidase was identified. Probing the restriction digests of HCMV (Towne and AD169) DNA with insert DNA from the immunoreactive lambda gt11 clone permitted us to localize the coding sequence within the long unique region between map coordinates of 0.62 and 0.64 of HCMV Towne and AD169 genomes. Using the same probe, a single transcript of 1.4 kb was detected in total RNA from HCMV-infected cells at late times after infection.

Prospects for the clinical management of human cytomegalovirus infections

Infection of susceptible populations by human cytomegalovirus (HCMV) is a significant public health problem in Western societies. Vaccination with live attenuated strains of HCMV has demonstrated some degree of clinical benefit but objections based on the possibility of these viruses becoming latent and their potential oncogenicity must be considered. Our knowledge of the biology and immunology of HCMV, although advancing rapidly, is still a long way short of being able to predict candidate subunit vaccines based on virus encoded proteins or glycoproteins. Treatment of the disease by injection of antibodies awaits a breakthrough and chemicals effective in the control of other human herpes viruses are disappointingly ineffective against HCMV. Clearly, prophylaxis is preferable to therapy and it is in the design of new effective vaccines that endeavours must be channelled so that we can control complications associated with severe clinical infection with this virus.